Literature DB >> 17275636

The effectiveness of warfarin dosing from a nomogram compared with house staff dosing.

Peter D Asnis1, Michael J Gardner, Anil Ranawat, Anne H Leitzes, Margaret G E Peterson, Anne R Bass.   

Abstract

The purpose of this study is to address the safety and efficacy of a warfarin dosing nomogram. Patients undergoing hip or knee arthroplasty were randomized to warfarin dosed by nomogram (n = 106) or by house staff (n = 110) during their hospital stay. The average daily dose of warfarin was 4.14 mg for the nomogram group and 4.18 mg for the house staff group. On postoperative day 4, the average international normalized ratio was 1.55 in the nomogram group compared with 1.59 in the house staff group. On postoperative day 4, 19.1% of the patients in the nomogram group had a therapeutic international normalized ratio, compared with 14.7% in the house staff group. There were no differences in bleeding or thrombotic complications in the 2 groups. This nomogram appears to be both safe and effective.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275636     DOI: 10.1016/j.arth.2006.03.006

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  10 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?

Authors:  Denis Nam; Anita Sadhu; Jeffrey Hirsh; James A Keeney; Ryan M Nunley; Robert L Barrack
Journal:  J Arthroplasty       Date:  2014-09-06       Impact factor: 4.757

3.  Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge.

Authors:  Nibal Chamoun; C Gabriela Macías; Jennifer L Donovan; Robert Klugman; Joel Gore; Pascale Salameh; Maichi T Tran
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

4.  Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol.

Authors:  Ettore Vulcano; Mark Gesell; Amanda Esposito; Yan Ma; Stavros G Memtsoudis; Alejandro Gonzalez Della Valle
Journal:  Int Orthop       Date:  2012-06-12       Impact factor: 3.075

5.  High incidence of complications from enoxaparin treatment after arthroplasty.

Authors:  Andrew S Neviaser; Charles Chang; Stephen Lyman; Alejandro Gonzales Della Valle; Steven B Haas
Journal:  Clin Orthop Relat Res       Date:  2009-08-11       Impact factor: 4.176

Review 6.  Quality measures and benchmarking for warfarin therapy.

Authors:  Daniel M Witt
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

7.  Predictors for moderate to severe acute postoperative pain after total hip and knee replacement.

Authors:  Spencer S Liu; Asokumar Buvanendran; James P Rathmell; Mona Sawhney; James J Bae; Mario Moric; Stephen Perros; Ashley J Pope; Lazaros Poultsides; Craig J Della Valle; Naomi S Shin; Colin J L McCartney; Yan Ma; Mahendrakumar Shah; Monica J Wood; Smith C Manion; Thomas P Sculco
Journal:  Int Orthop       Date:  2012-07-29       Impact factor: 3.075

8.  Use of signals and systems engineering to improve the safety of warfarin initiation.

Authors:  G Hyun; J Li; A R Bass; A Mohapatra; S C Woller; H Lin; C Eby; G A McMillin; B F Gage
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

9.  VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.

Authors:  Alejandro González Della Valle; Saurabh Khakharia; Charles J Glueck; Nicole Taveras; Ping Wang; Robert N Fontaine; Eduardo A Salvati
Journal:  Clin Orthop Relat Res       Date:  2008-11-26       Impact factor: 4.176

10.  Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.

Authors:  Alexander G G Turpie; André C Schmidt; Reinhold Kreutz; Michael R Lassen; Waheed Jamal; Lorenzo Mantovani; Sylvia Haas
Journal:  Vasc Health Risk Manag       Date:  2012-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.